Jefferies Financial Group reiterated their buy rating on shares of GlaxoSmithKline (LON:GSK) in a research note released on Friday, ThisIsMoney.Co.Uk reports.
A number of other equities research analysts have also commented on GSK. HSBC set a GBX 1,820 ($23.78) price target on GlaxoSmithKline and gave the company a buy rating in a research report on Friday, January 25th. Goldman Sachs Group set a GBX 1,900 ($24.83) price target on GlaxoSmithKline and gave the company a buy rating in a research report on Thursday, January 31st. Deutsche Bank reissued a hold rating and issued a GBX 1,520 ($19.86) price target on shares of GlaxoSmithKline in a research report on Wednesday, February 6th. UBS Group reissued a buy rating and issued a GBX 1,700 ($22.21) price target on shares of GlaxoSmithKline in a research report on Thursday, February 7th. Finally, Credit Suisse Group set a GBX 1,600 ($20.91) price target on GlaxoSmithKline and gave the company a neutral rating in a research report on Thursday, February 7th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of Hold and an average target price of GBX 1,526.14 ($19.94).
LON GSK opened at GBX 1,582 ($20.67) on Friday. The firm has a market capitalization of $78.26 billion and a P/E ratio of 20.15. GlaxoSmithKline has a 12 month low of GBX 1,408.80 ($18.41) and a 12 month high of GBX 1,648.80 ($21.54). The company has a quick ratio of 0.45, a current ratio of 0.72 and a debt-to-equity ratio of 942.07.
The firm also recently announced a dividend, which will be paid on Thursday, July 11th. Stockholders of record on Thursday, May 16th will be given a dividend of GBX 19 ($0.25) per share. This represents a dividend yield of 1.22%. The ex-dividend date is Thursday, May 16th. GlaxoSmithKline’s dividend payout ratio is presently 1.17%.
In other GlaxoSmithKline news, insider Manvinder Singh Banga bought 458 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was purchased at an average cost of GBX 1,568 ($20.49) per share, with a total value of £7,181.44 ($9,383.82).
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Further Reading: Growth Stocks, What They Are, What They Are Not
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.